Search clinical trials for: AZD 1222

Total 270691 results

Celgene

Completed

Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

Lymphoma | Lymphoma, Large B-Cell, Diffuse | Glioblastoma | Multiple Myeloma | Primary Central Nervous System Lymphoma | Pleiotropic Pathway Modifier

United States, Spain, Belgium, France, Italy
Rznomics, Inc.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma

Glioblastoma
Bayer

Completed

Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A." (POTTER 10)

Hemophilia A

Italy
Bayer

Completed

Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery (NO PEACKS)

Hemophilia A

Germany, Spain, Austria, Italy, Slovenia, Greece, Netherlands
Bayer

Completed

Kogenate FS Regulatory Post-Marketing Surveillance (KG0910KR)

Hemophilia A

Korea, Republic of
Bayer

Completed

Evaluation of the Stinging Potential in Human Eyes

Sunscreen Agents

United States
TG Therapeutics, Inc.

Active, not recruiting

Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

Australia, Poland
Kissei Pharmaceutical Co., Ltd.

Completed

Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Healables Ltd.
Wolfson Medical Center

Enrolling by invitation

A Telehealth Study of a Wearable Electroceutical & Sports Sleeve for Knee Osteoarthritis Pain Relief & Improved Function (HEAL01WMCOA1)

Osteoarthritis, Knee

Israel
Organon and Co

Completed

To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)

Schizophrenia
Sun Pharmaceutical Industries Limited

Withdrawn

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)

Plaque-type Psoriasis
National Cancer Institute (NCI)

Completed

Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors

Recurrent Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Stage III Renal Cell Cancer | Recurrent Melanoma | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Melanoma | Stage IV Ovarian Epithelial Cancer | Stage IIIB Breast Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell... and other conditions

United States
Bayer

Completed

Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients (OPTIMS)

Haemophilia A

France, Italy
Bayer

Completed

Prophylaxis Versus on Demand Treatment for Children With Hemophilia A

Hemophilia A

China
Bayer

Completed

Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America

Hemophilia A | Blood Coagulation Disorders

Mexico, Venezuela
Bayer

Completed

Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A

Blood Coagulation Disorders | Hematologic Disease

United States, Germany, United Kingdom, Canada
Bayer

Completed

EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS

Hemophilia A

Croatia, Germany, Saudi Arabia, Kazakhstan, Romania, Russian Federation, Slovenia, Bahrain, United Arab Emirates, Bosnia and Herzegovina, Israel, Kuwait, Libyan Arab Jamahiriya, Morocco, Oman, Qatar, Tunisia
Bayer

Completed

Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222

Hemophilia A

Bulgaria
Bayer

Completed

Prophylaxis Versus On-demand Therapy Through Economic Report (POTTER)

Hemophilia A

Italy
TG Therapeutics, Inc.

Terminated

Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) (ULTRA-V)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Bayer

Completed

Russian Kogenate Pediatric Study

Hemophilia A

Russian Federation
Cerecin

Completed

Study to Compare the Pharmacokinetics of Tricaprilin Formulations and a Placebo on Ketone Body Production

Alzheimer Disease

Australia
Biotronik Australia Pty Ltd.

Completed

BIO|CONCEPT.Renamic Neo Study

Medical Devices

Australia
Cerecin

Withdrawn

Medical Food Formulation Pharmacokinetic (PK) Study in Medium Chain Triglycerides

Alzheimer Disease
Therapeutics, Inc.

Completed

Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression

Plaque Psoriasis

United States
Kissei Pharmaceutical Co., Ltd.

Completed

Long-term Study of KAD-1229 in Type 2 Diabetes Patients

Type 2 Diabetes

Japan
Bayer

Completed

Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment (SPINART)

Hemophilia A

United States, Bulgaria, Romania, Argentina
Cerecin
Celerion

Completed

Evaluation of PK of Caprylic Triglyceride Oil, AC-1202, AC-1204, and Axona on Ketone Body Production

Healthy

United States
Ratio Therapeutics, Inc.

Completed

Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer

Prostate Cancer

United States
University of Alabama at Birmingham

Terminated

Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL) (CHOP U2)

Mantle Cell Lymphoma

United States
Wockhardt
Clinartis

Completed

To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment

Renal Impairment

United States
Bayer

Terminated

BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A

Hemophilia A

Belgium, Italy, Spain, United States, Canada, Switzerland, Estonia, Taiwan, France, Chile, Netherlands, United Kingdom, Austria, New Zealand, South Africa, Romania, Croatia, Israel, Germany, Poland, Australia, Denmark, Turkey, Argentina, Lithuan... and more
Que Oncology
Syneos Health

Completed

Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor

Vasomotor Symptoms (VMS)

United States, New Zealand, Australia
Joel Thompson, PhD

Terminated

Thoracoscopic Lung Cancer Staging With the Use of Intraoperative Ultrasound

Lung Cancer

United States
Bayer

Completed

Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A (Leopold I)

Hemophilia A | Blood Coagulation Disorders

Spain, Taiwan, Austria, United States, Germany, Thailand, United Kingdom, Italy, Turkey, Croatia, Serbia, Poland, Israel, Sweden, Indonesia, Argentina, Norway, South Africa, India, Hong Kong, Denmark, Pakistan
AbbVie

Completed

Phase 2, Multicenter, Open-Label Extension Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study

Rheumatoid Arthritis
Celgene

Completed

A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.

Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin

France, Italy, Netherlands
Que Oncology

Completed

Dose Escalation Study in Female Subjects With Breast Cancer Receiving Aromatase Inhibitor or Tamoxifen

Vasomotor Symptoms (VMS)
University of Chicago

Active, not recruiting

Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL

CLL | B-cell Non Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

Recurrent Small Lymphocytic Lymphoma | B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Celgene

Completed

A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (ENHANCE)

Leukemia, Lymphocytic, Chronic, B-Cell

Spain, United States, Italy, Germany, Austria
TaiwanJ Pharmaceuticals Co., Ltd

Not yet recruiting

Effect of JKB-122 on Prednisolone and Azathioprine Induced Remission in Autoimmune Hepatitis (AIH)

Autoimmune Hepatitis
AbbVie

Terminated

A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197

Psoriatic Arthritis

Australia, Bulgaria, Czech Republic, Germany, Hungary, Latvia, New Zealand, Poland, Romania, Spain
TG Therapeutics, Inc.

Terminated

Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

Chronic Lymphocytic Leukemia

United States
Ascentage Pharma Group Inc.

Terminated

Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

Small Cell Lung Cancer

United States, Australia
Bayer

Completed

Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment (ECHO)

Hemophilia A

United States, Japan, United Kingdom, Spain
Organon and Co

Completed

40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)

Bipolar Disorder
Bayer

Completed

Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980

Hemophilia A

United States
Santen Inc.

Completed

Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects

Age-Related Macular Degeneration

United States, Philippines
Massachusetts General Hospital
TG Therapeutics

Terminated

Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

Lymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2

United States

3

Subscribe